Cargando…

Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patients

BACKGROUND: Meropenem is a carbapenem antibiotic commonly used in critically ill patients to treat severe infections. The available pharmacokinetic (PK) data has been mostly obtained from healthy volunteers as well as from clinical studies addressing selected populations, often excluding the elderly...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goncalves-Pereira, João, Silva, Nuno Elvas, Mateus, André, Pinho, Catarina, Povoa, Pedro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4006523/ https://www.ncbi.nlm.nih.gov/pubmed/24731745 http://dx.doi.org/10.1186/2050-6511-15-21

Ejemplares similares

Evaluation of gentamicin first-dose pharmacokinetics in septic critically ill patients: pilot study
por: Pereira, JC Gonçalves, et al.
Publicado: (2009)

Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams
por: Gonçalves-Pereira, Joao, et al.
Publicado: (2011)

Meropenem Target Attainment and Population Pharmacokinetics in Critically Ill Septic Patients with Preserved or Increased Renal Function
por: Gijsen, Matthias, et al.
Publicado: (2022)

Pharmacokinetics of meropenem in critically ill patients in Saudi Arabia
por: Alsultan, Abdullah, et al.
Publicado: (2021)

Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients
por: Gan, Yuhong, et al.
Publicado: (2023)

Continuous Infusion of Piperacillin/Tazobactam in Septic Critically Ill Patients—A Multicenter Propensity Matched Analysis
por: Gonçalves-Pereira, João, et al.
Publicado: (2012)

The effect of meropenem versus piperacillin-tazobactam in critically ill patients with sepsis and septic shock()
por: Sun, Yang, et al.
Publicado: (2023)

Pharmacokinetics of meropenem during continuous renal replacement therapy in critically ill patients
por: Solé Violan, J, et al.
Publicado: (2014)

Optimizing Antimicrobial Drug Dosing in Critically Ill Patients
por: Póvoa, Pedro, et al.
Publicado: (2021)

Evaluation of pharmacokinetic and pharmacodynamic parameters of meropenem in critically ill patients with acute kidney disease
por: Hassanpour, Rezvan, et al.
Publicado: (2021)

Population Pharmacokinetics of Meropenem in Critically Ill Korean Patients and Effects of Extracorporeal Membrane Oxygenation
por: Lee, Dong-Hwan, et al.
Publicado: (2021)

Pharmacokinetics of meropenem in septic patients on sustained low-efficiency dialysis: a population pharmacokinetic study
por: Braune, Stephan, et al.
Publicado: (2018)

Impact of cumulative fluid balance on the pharmacokinetics of extended infusion meropenem in critically ill patients with sepsis
por: Pařízková, Renata Černá, et al.
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Meropenem by Extended or Continuous Infusion in Low Body Weight Critically Ill Patients
por: Luque, Sonia, et al.
Publicado: (2021)

External Evaluation of Population Pharmacokinetic Models to Inform Precision Dosing of Meropenem in Critically Ill Patients
por: Yang, Nan, et al.
Publicado: (2022)

611. Meropenem Dosage Optimization in Critically Ill Patients Based on a Population Pharmacokinetic Approach.
por: Romano-Aguilar, Melissa, et al.
Publicado: (2022)

No clinically relevant removal of meropenem by cytokine adsorber CytoSorb(®) in critically ill patients with sepsis or septic shock
por: Liebchen, Uwe, et al.
Publicado: (2021)

Pharmacokinetics and Monte Carlo Simulation of Meropenem in Critically Ill Adult Patients Receiving Extracorporeal Membrane Oxygenation
por: Lee, Jae Ha, et al.
Publicado: (2021)

Meropenem pharmacokinetics in critically ill patients with or without burn treated with or without continuous veno‐venous haemofiltration
por: Selig, Daniel J., et al.
Publicado: (2021)

Acute-on-chronic liver failure alters meropenem pharmacokinetics in critically ill patients with continuous hemodialysis: an observational study
por: Grensemann, Jörn, et al.
Publicado: (2020)

Clinical outcomes of empirical high-dose meropenem in critically ill patients with sepsis and septic shock: a randomized controlled trial
por: Lertwattanachai, Tospon, et al.
Publicado: (2020)

Continuous infusion of meropenem in critically ill patients: practical considerations
por: Taccone, Fabio Silvio
Publicado: (2012)

Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial
por: Benítez-Cano, Adela, et al.
Publicado: (2020)

Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients Are Not Affected by Extracorporeal Membrane Oxygenation: A Matched Cohort Analysis
por: Gijsen, Matthias, et al.
Publicado: (2021)

2551. Assessing Meropenem Concentrations in Children with Septic Shock: Population-Based Pharmacokinetic (PK) Modeling of Meropenem Demonstrates Variability from Acute Kidney (AKI) to Augmented Renal Clearance (ARC)
por: Le, Jennifer, et al.
Publicado: (2023)

402 Pharmacokinetics of Extended vs Intermittent Intravenous Infusion of Meropenem in Critically Ill Patients Receiving Continuous Veno-Venous Haemofiltration
por: Frippiat, Frédéric, et al.
Publicado: (2014)

Population pharmacokinetics of standard-dose meropenem in critically ill patients on continuous renal replacement therapy: a prospective observational trial
por: Onichimowski, Dariusz, et al.
Publicado: (2020)

Dose Optimization of Meropenem in Patients on Veno-Arterial Extracorporeal Membrane Oxygenation in Critically Ill Cardiac Patients: Pharmacokinetic/Pharmacodynamic Modeling
por: Kang, Soyoung, et al.
Publicado: (2022)

Comparison of empirical high-dose and low-dose of meropenem in critically ill patients with sepsis and septic shock: A randomized controlled study protocol
por: Ye, Xiaolin, et al.
Publicado: (2020)

Systematic Evaluation of Pharmacokinetic Models for Model-Informed Precision Dosing of Meropenem in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy
por: Schatz, Lea Marie, et al.
Publicado: (2023)

An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam
por: Wenzler, Eric, et al.
Publicado: (2020)

Clearance of meropenem during continuous renal replacement therapy in critically ill patients
por: Thalhammer, F, et al.
Publicado: (1999)

Meropenem-Resistant Pandoraea Pneumonia in a Critically Ill Patient With COVID-19
por: Dlewati, Mohammad M, et al.
Publicado: (2021)

Impact of High Body Weight on Mortality in Critically Ill Patients Receiving Meropenem for Pneumonia
por: Gao, Xiaofang, et al.
Publicado: (2019)

Subsyndromal Delirium in Critically Ill Patients—Cognitive and Functional Long-Term Outcomes
por: Paulino, Maria Carolina, et al.
Publicado: (2023)

Biomarker-guided antibiotic therapy in adult critically ill patients: a critical review
por: Póvoa, Pedro, et al.
Publicado: (2012)

Continuous infusion versus intermittent administration of meropenem in critically ill patients: a pilot study
por: Thalhammer, F, et al.
Publicado: (1999)

Meropenem Model-Informed Precision Dosing in the Treatment of Critically Ill Patients: Can We Use It?
por: Li, Letao, et al.
Publicado: (2023)

Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?
por: Carlier, Mieke, et al.
Publicado: (2013)

Pharmacokinetic and Pharmacodynamic Efficacies of Continuous versus Intermittent Administration of Meropenem in Patients with Severe Sepsis and Septic Shock: A Prospective Randomized Pilot Study
por: Zhao, Hui-Ying, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_11e00v4umlplo8te2a3irmchl0